NSE: DCAL · Pharmaceuticals
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Dishman Carbogen Amcis Limited is a global pharmaceutical services company specialising in contract research and manufacturing (CRAMS) and the production of marketable molecules. The company provides a diverse range of products including active pharmaceutical ingredients, fine chemicals, and specialised reagents for the global healthcare and cosmetic industries.
The company operates through a B2B model, providing outsourced research and manufacturing services to global pharmaceutical firms alongside the direct supply of bulk drugs and fine chemicals. Revenue is generated through long-term service contracts and the commercial sale of proprietary chemical and vitamin D-based products.
Growth is driven by the increasing global demand for outsourced pharmaceutical research and the expansion of high-potency active pharmaceutical ingredient manufacturing capabilities. The company continues to leverage its expertise in complex chemical synthesis to support the development pipelines of global pharmaceutical partners.
Unlock AI insights, financials, peers and live data on Dishman Carbogen Amcis Limited and 5,000+ companies — free.
REVENUE
₹2,756 Cr
TTM · consolidated
NET PROFIT
₹-116 Cr
TTM · consolidated
EPS
₹-7.39
TTM · consolidated
RETURN ON EQUITY
-1.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
0.8%
TTM · consolidated
P/E
-23.4×
Q2 FY27 · consolidated
EV/EBITDA
11.4x
Q2 FY27 · consolidated
EBITDA MARGIN
15.5%
TTM · consolidated
NET PROFIT MARGIN
-13.2%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.5%
Q2 FY27 · consolidated
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Dishman Carbogen Amcis LimitedDCAL | ₹2,711 Cr | -23.4× | 11.40 | -0.1% | 15.5% | -1.8% | 0.8% | -30.6% |
Ind-Swift Laboratories LimitedINDSWFTLAB | ₹3,142 Cr | 37.0× | 18.97 | 66.4% | 19.8% | 6.0% | 7.4% | +248.2% |
HikalHIKAL | ₹2,743 Cr | -556.2× | 11.88 | 8.9% | 15.3% | -0.4% | 2.4% | -3.6% |
Fredun Pharmaceuticals LimitedFREDUN | ₹2,482 Cr | 20.3× | 20.56 | — | 15.1% | 21.7% | 37.5% | -16.1% |
Sakar HealthcareSAKAR | ₹2,319 Cr | 54.2× | 25.46 | 48.0% | 30.8% | 13.2% | 17.8% | +163.9% |
Sai Parenterals LimitedSAIPARENT | ₹2,195 Cr | 83.2× | 24.28 | — | 14.9% | 5.0% | 6.1% | — |
As of Q2 FY27
Dishman Carbogen Amcis Limited
NSE: DCAL · Pharmaceuticals
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Dishman Carbogen Amcis Limited is a global pharmaceutical services company specialising in contract research and manufacturing (CRAMS) and the production of marketable molecules. The company provides a diverse range of products including active pharmaceutical ingredients, fine chemicals, and specialised reagents for the global healthcare and cosmetic industries.
The company operates through a B2B model, providing outsourced research and manufacturing services to global pharmaceutical firms alongside the direct supply of bulk drugs and fine chemicals. Revenue is generated through long-term service contracts and the commercial sale of proprietary chemical and vitamin D-based products.
Growth is driven by the increasing global demand for outsourced pharmaceutical research and the expansion of high-potency active pharmaceutical ingredient manufacturing capabilities. The company continues to leverage its expertise in complex chemical synthesis to support the development pipelines of global pharmaceutical partners.
Unlock AI insights, financials, peers and live data on Dishman Carbogen Amcis Limited and 5,000+ companies — free.
REVENUE
₹2,756 Cr
TTM · consolidated
NET PROFIT
₹-116 Cr
TTM · consolidated
EPS
₹-7.39
TTM · consolidated
RETURN ON EQUITY
-1.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
0.8%
TTM · consolidated
P/E
-23.4x
Q2 FY27 · consolidated
EV/EBITDA
11.4x
Q2 FY27 · consolidated
EBITDA MARGIN
15.5%
TTM · consolidated
NET PROFIT MARGIN
-13.2%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.5%
Q2 FY27 · consolidated
As of Q2 FY27